172 related articles for article (PubMed ID: 16344254)
1. Dosimetric quantifiers for low-dose-rate prostate brachytherapy: is V(100) superior to D(90)?
Papagikos MA; Deguzman AF; Rossi PJ; McCullough DL; Clark PE; Lee WR
Brachytherapy; 2005; 4(4):252-8. PubMed ID: 16344254
[TBL] [Abstract][Full Text] [Related]
2. Dosimetry and cancer control after low-dose-rate prostate brachytherapy.
Robert Lee W; Deguzman AF; McMullen KP; McCullough DL
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):52-9. PubMed ID: 15629593
[TBL] [Abstract][Full Text] [Related]
3. A simple model predicts freedom from biochemical recurrence after low-dose rate prostate brachytherapy alone.
Papagikos MA; Rossi PJ; Urbanic JJ; deGuzman AF; McCullough DL; Clark PE; Lee WR
Am J Clin Oncol; 2007 Apr; 30(2):199-204. PubMed ID: 17414471
[TBL] [Abstract][Full Text] [Related]
4. Pretreatment prostate-specific antigen velocity is associated with freedom from biochemical recurrence of prostate cancer after low-dose-rate prostate brachytherapy alone.
Rossi PJ; Urbanic J; Clark PE; McCullough DL; Lee WR
Brachytherapy; 2008; 7(4):286-9. PubMed ID: 18928924
[TBL] [Abstract][Full Text] [Related]
5. Percentage of positive biopsies associated with freedom from biochemical recurrence after low-dose-rate prostate brachytherapy alone for clinically localized prostate cancer.
Rossi PJ; Clark PE; Papagikos MA; McCullough DL; Lee WR
Urology; 2006 Feb; 67(2):349-53. PubMed ID: 16461084
[TBL] [Abstract][Full Text] [Related]
6. Cancer control after low-dose-rate prostate brachytherapy performed by a multidisciplinary team with no previous prostate brachytherapy experience.
McMullen KP; deGuzman AF; McCullough DL; Lee WR
Urology; 2004 Jun; 63(6):1128-31. PubMed ID: 15183965
[TBL] [Abstract][Full Text] [Related]
7. Equivalent uniform dose, D(90), and V(100) correlation with biochemical control after low-dose-rate prostate brachytherapy for clinically low-risk prostate cancer.
Miles EF; Nelson JW; Alkaissi AK; Das S; Clough RW; Anscher MS; Oleson JR
Brachytherapy; 2008; 7(2):206-11. PubMed ID: 18359669
[TBL] [Abstract][Full Text] [Related]
8. Biologically effective dose (BED) correlation with biochemical control after low-dose rate prostate brachytherapy for clinically low-risk prostate cancer.
Miles EF; Nelson JW; Alkaissi AK; Das S; Clough RW; Broadwater G; Anscher MS; Chino JP; Oleson JR
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):139-46. PubMed ID: 19836161
[TBL] [Abstract][Full Text] [Related]
9. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy.
Ho AY; Burri RJ; Cesaretti JA; Stone NN; Stock RG
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):16-22. PubMed ID: 19289266
[TBL] [Abstract][Full Text] [Related]
10. Young men have equivalent biochemical outcomes compared with older men after treatment with brachytherapy for prostate cancer.
Burri RJ; Ho AY; Forsythe K; Cesaretti JA; Stone NN; Stock RG
Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1315-21. PubMed ID: 20044216
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of dosimetric parameters and disease response after 125 iodine transperineal brachytherapy for low- and intermediate-risk prostate cancer.
Morris WJ; Keyes M; Palma D; McKenzie M; Spadinger I; Agranovich A; Pickles T; Liu M; Kwan W; Wu J; Lapointe V; Berthelet E; Pai H; Harrison R; Kwa W; Bucci J; Racz V; Woods R
Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1432-8. PubMed ID: 19036530
[TBL] [Abstract][Full Text] [Related]
12. Dosimetric predictors of biochemical control of prostate cancer in patients randomised to external beam radiotherapy with a boost of high dose rate brachytherapy.
Hoskin PJ; Rojas AM; Ostler PJ; Hughes R; Bryant L; Lowe GJ
Radiother Oncol; 2014 Jan; 110(1):110-3. PubMed ID: 24100150
[TBL] [Abstract][Full Text] [Related]
13. Regional dose metrics as predictors of biochemical failure and local recurrence after low-dose-rate prostate brachytherapy.
Spadinger I; Chu J; Afsari Golshan M; Keyes M; Pickles T; Hamm J; Morris WJ
Brachytherapy; 2015; 14(3):350-8. PubMed ID: 25638507
[TBL] [Abstract][Full Text] [Related]
14. Predicting biochemical tumor control after brachytherapy for clinically localized prostate cancer: The Memorial Sloan-Kettering Cancer Center experience.
Zelefsky MJ; Chou JF; Pei X; Yamada Y; Kollmeier M; Cox B; Zhang Z; Schechter M; Cohen GN; Zaider M
Brachytherapy; 2012; 11(4):245-9. PubMed ID: 21925957
[TBL] [Abstract][Full Text] [Related]
15. Postimplant analysis of transperineal interstitial permanent prostate brachytherapy: evidence for a learning curve in the first year at a single institution.
Lee WR; deGuzman AF; Bare RL; Marshall MG; McCullough DL
Int J Radiat Oncol Biol Phys; 2000 Jan; 46(1):83-8. PubMed ID: 10656377
[TBL] [Abstract][Full Text] [Related]
16. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
[TBL] [Abstract][Full Text] [Related]
17. Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer.
Wong WW; Schild SE; Vora SA; Halyard MY
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):24-9. PubMed ID: 15337536
[TBL] [Abstract][Full Text] [Related]
18. Relationship between Day 0 dosimetric parameters and biochemical relapse-free survival in patients treated with transperineal permanent prostate interstitial brachytherapy with (125)I seeds.
Garrán C; Ciérvide R; Cambeiro M; Moreno-Jiménez M; Ramos LI; Martínez-Monge R
Brachytherapy; 2010; 9(1):8-14. PubMed ID: 19846350
[TBL] [Abstract][Full Text] [Related]
19. Twelve-month prostate-specific antigen values and perineural invasion as strong independent prognostic variables of long-term biochemical outcome after prostate seed brachytherapy.
Ding W; Lee J; Chamberlain D; Cunningham J; Yang L; Tay J
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):962-7. PubMed ID: 22494584
[TBL] [Abstract][Full Text] [Related]
20. Monotherapeutic brachytherapy for clinically organ-confined prostate cancer.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Adamovich E
W V Med J; 2005; 101(4):168-71. PubMed ID: 16296198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
